Brief: Compass Pathways Announces Dosing Complete For All Participants In Part A Of Phase 3 Comp005 Trial Of Comp360 Psilocybin
22/04/2025 11:03
April 22 (Reuters) - Compass Pathways PLC CMPS.O: COMPASS PATHWAYS ANNOUNCES DOSING COMPLETE FOR ALL PARTICIPANTS IN PART A OF PHASE 3 COMP005 TRIAL OF COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION COMPASS PATHWAYS PLC - TOP-LINE 6-WEEK PRIMARY ENDPOINT RESULTS EXPECTED IN LATE JUNE Source text: ID:nBw31H0b6a Further company coverage: CMPS.O
Recent news on COMPASS Pathways
See all newsCompass Pathways PLC reports results for the quarter ended September 30 - Earnings Summary
Corrected: Compass Pathways Q3 net loss narrows on lower R&D charges
Corrected: BRIEF-COMPASS Pathways Q3 EPS USD -0.31
Psychedelic drug developers fall after Usona submits depressive drug application
Compass Pathways PLC expected to post a loss of 45 cents a share - Earnings Preview